Type 2 Diabetes Mellitus (T2DM)

A metabolic disease that is straining healthcare systems worldwide at epidemic proportions.

According to the latest data released by the International Diabetes Federation (IDF) in 2025, 589 million adults (20-79 years) were living with diabetes in 2024. This number continues to rise and is predicted to reach 853 million by 2050, placing a heavy burden on patients, families and healthcare systems across the globe.1

T2DM is a complex, multifactorial disease requiring more treatment options.

T2DM is caused primarily by defective insulin secretion by pancreatic β-cells and the inability of insulin-sensitive tissues to respond appropriately leading to a disruption in glucose homeostasis.

Despite the many treatment advancements in recent years, only half of the people living with T2DM are meeting goals for lowering their blood glucose levels. When their disease is not managed properly, it often leads to serious complications, including kidney disease, nerve damage, heart attack and stroke.

Further, T2DM commonly coexists with other metabolic abnormalities such as hypertension, hyperlipidemia, obesity, and MASH that can exacerbate T2DM and lead to a worse prognosis with increased risk for mortality and cardiovascular outcomes.2,3

Type 2 diabetes diagram to show how all diseases are interconnected.

Driving progress by exploring innovative ways to treat and manage T2DM

There is a significant need for antidiabetic treatment innovation that can more comprehensively address metabolic risk factors beyond glycemic control. We see an opportunity to apply emerging modalities and mechanisms to advance treatment beyond injections to improve ease of patient use and treatments with improved tolerability profiles – ensuring long-term adherence.

References
1. IDF Diabetes Atlas 2025
2. Dufour J-F, Scherer R, Balp M-M, McKeena SJ, Janssens N, Lopez P, et al. The global epidemiology of nonalcoholic steatohepatitis (NASH) and associated risk factors–A targeted literature review. Endocrine and Metabolic Science. 2021;3:100089.
3. Rawshani A, Rawshani A, Franzen S, Sattar N, Eliasson B, Svensson AM, et al. Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2018;379(7):633-44.